Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) had its price objective dropped by analysts at Canaccord Genuity Group from $74.00 to $54.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the stock.
NTLA has been the topic of a number of other research reports. Citigroup lowered their target price on Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Chardan Capital reiterated a "buy" rating and set a $68.00 price target on shares of Intellia Therapeutics in a research note on Friday, May 9th. Truist Financial decreased their price target on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Wall Street Zen upgraded Intellia Therapeutics to a "sell" rating in a research note on Monday, March 3rd. Finally, Barclays decreased their price target on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $34.95.
Check Out Our Latest Analysis on NTLA
Intellia Therapeutics Trading Up 6.7%
NASDAQ NTLA traded up $0.51 on Tuesday, reaching $8.09. The stock had a trading volume of 7,207,575 shares, compared to its average volume of 2,757,291. The business has a 50 day moving average price of $7.93 and a 200 day moving average price of $10.06. Intellia Therapeutics has a 1 year low of $5.90 and a 1 year high of $28.18. The company has a market capitalization of $837.99 million, a price-to-earnings ratio of -1.49 and a beta of 2.33.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, beating analysts' consensus estimates of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to analysts' expectations of $11.39 million. During the same quarter last year, the firm earned ($1.12) EPS. The business's revenue for the quarter was down 42.6% compared to the same quarter last year. On average, analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Intellia Therapeutics
Several large investors have recently made changes to their positions in NTLA. GF Fund Management CO. LTD. acquired a new position in Intellia Therapeutics in the 4th quarter valued at approximately $25,000. Northwestern Mutual Wealth Management Co. raised its holdings in Intellia Therapeutics by 56.4% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company's stock valued at $33,000 after acquiring an additional 1,655 shares in the last quarter. Sterling Capital Management LLC raised its holdings in Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock valued at $37,000 after acquiring an additional 2,867 shares in the last quarter. Harbour Investments Inc. raised its holdings in Intellia Therapeutics by 76.7% in the 1st quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock valued at $37,000 after acquiring an additional 2,264 shares in the last quarter. Finally, Whipplewood Advisors LLC acquired a new position in Intellia Therapeutics in the 4th quarter valued at approximately $40,000. Institutional investors and hedge funds own 88.77% of the company's stock.
Intellia Therapeutics Company Profile
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Recommended Stories
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
